Skip navigation
Watchlist Sponsored By :

Current DateTime: 01:02:54 22 Nov 2008
LinksList Documentid: 24890560
  • Risk & You

      It's a risky world out there. Whether it's investment or retirement, career or home you can take steps to lower your risk profile.

  • Wall Street In Crisis

      With shock after shock to the world's financial system, the credit crunch continues to drive a major reconfiguration of the Wall Street landscape.

  • Protecting Your Portfolio

      Credit Crunch. Recession. Bear Market. There's a triple threat out there for investors. Here's a guide to managing your money.

Study Refutes Need for Superbug Tests
By Mike Huckman, CNBC Pharmaceutical Reporter | 11 Mar 2008 | 04:02 PM ET
Text Size

Giving everyone who's admitted to a hospital a quick test for the so-called "Superbug" doesn't significantly cut the number of infections and isn't cost-effective.

That's the conclusion of the biggest study yet that's just been published in the Journal of the American Medical Association. The journal also says in an editorial that hospitals can control the potentially fatal staph infections by using basic sanitary measures rather than "expensive" tests.

Researchers looked at nearly 22-thousand patients at a Swiss hospital who either got screened for the bacterial infection commonly known as MRSA or who used standard infection controls like hand gel.  And they report that the universal testing did not reduce the incidence of MRSA infections.

Cepheid [CPHD  Loading...      ()   ] and Becton Dickinson [BDX  Loading...      ()   ] make MRSA tests which can give results much faster than the one used in the study and a few other companies are working on next-generation screening systems.

Cepheid CEO John Bishop told CNBC, "To say that it's (the MRSA test) not effective is an overstatement."  Mr. Bishop said that MRSA is much less prevalent in Switzerland than in the U.S., so he argues it is much more difficult to show a reduction in infection rates in Switzerland than it is here.  

In an email, Becton says this is just one "data point" and that many other studies have shown that testing for MRSA saves lives and money.

© 2008 CNBC.com

HOME  |  NEWS  |  MARKETS  |  EARNINGS  |  INVESTING  |  VIDEO  |  CNBC TV  |  CNBC PLUS  |  CNBC MOBILE  |  CNBC HD+
About CNBC   |   Site Map   |   Privacy Policy   |   Terms of Service   |   Advertise   |   Help   |   Feedback   |   Video Reprints
  Data is a real-time snapshot   *Data is delayed at least 15 minutes

Global Business and Financial News, Stock Quotes, and Market Data and Analysis